Pandelakis A. Koni, PhD MBA, joined the Parker Institute to help expand strategic approaches to immunotherapy and collaborative research programs, principally in cellular therapy areas. His background spans broad molecular, cellular and in vivo mouse immunology with over 19 years’ leadership experience. He has a long track record of collaboration and discoveries, and has co-authored over 50 publications in Immunity, Nature Immunology and Nature among others.
After a post-doctoral fellowship at the Babraham Institute in the U.K., Dr. Koni joined the laboratory of Richard Flavell at Yale (1995-1999) where he led lymphotoxin-beta and vascular cell adhesion molecule-1 (VCAM-1) research projects. In 1999, he became an Assistant Professor at the Medical College of Georgia (now a part of Augusta University) and also concurrently led a research group as a Part-time Team Leader at the RIKEN Research Center for Allergy and Immunology (Chiba, Japan; 2002-2004) before being promoted to Associate Professor (2004), where he discovered a significant role for VCAM-1 in lymphocyte recirculation to the bone marrow and engaged in projects dissecting the immune regulatory roles of various antigen-presenting cell subsets. Resources that he produced led to many studies in collaboration with others regarding antigen presentation by various professional and non-professional antigen presenting cell types. He then joined the Georgia Cancer Center at Augusta University as an Associate Member (2013) where he focused on how to render cellular therapies resistant against multiple mechanisms of immune suppression in cancer, to prevent tumor ‘escape’ from immunotherapy.
Dr Koni has a bachelor of science degree in Microbiology and Microbial Technology from the University of Warwick, a Ph.D. in Biochemistry from the University of Cambridge and an M.B.A. from Imperial College London.